Severe prolonged red blood cell aplasia and thrombocytopenia induced by parvovirus B19 infection in a patient with sarcoidosis

Clinical Infectious Diseases

Volumn 36, Issue 2, 2003, Pages 229-233

  Viallard, Jean François ^a,f   Parrens, Marie ^b   Hermine, Olivier ^d   Boiron, Jean Michel ^c,e   Lafon, Marie Edith ^g   Marit, Gérald ^c,e   Reiffers, Josy ^c,e   Pellegrin, Jean Luc ^a  

^a Serv de Med Nucleaire   (France)

^b Laboratoire d'Anatomopathologie   (France)

^c Service d'Hématologie   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e HÔPITAL PELLEGRIN   (France)

^f HAUT LÉVÊQUE HOSPITAL   (France)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 2; POLYCLONAL ANTIBODY; PREDNISOLONE; VIRUS ANTIBODY;

ACROMEGALY; ADULT; ANEMIA; ANTIBODY BLOOD LEVEL; ARTICLE; CASE REPORT; CELL STIMULATION; CYTOKINE RELEASE; ERYTHROCYTE APLASIA; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MONONUCLEAR CELL; PARVOVIRUS; PRIORITY JOURNAL; RETICULOCYTE; SARCOIDOSIS; SPLENOMEGALY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VIRUS INFECTION;

ADULT; FEMALE; HUMANS; INTERFERON TYPE II; PARVOVIRIDAE INFECTIONS; PARVOVIRUS; RED-CELL APLASIA, PURE; SARCOIDOSIS; THROMBOCYTOPENIA;

EID: 0037439345     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/345745     Document Type: Article

References (23)

1. Ozawa K, Kurtzman G, Young N. Replication of the B19 parvovirus in human bone marrow cell cultures. Science 1986; 233:883-6.
2. Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152:257-65.
3. Pattison JR, Jones SE, Hodgson J, et al. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet 1981; 1(8221):664-5.
4. Young NS. Hematologic and hematopoietic consequences of B19 parvovirus infection. Semin Hematol 1988;25:159-72.
5. Saarinen UM, Chorba TL, Tattersall P, et al. Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood 1986; 67:1411-7.
6. Mortimer PP, Humphries RK, Moore JG, Purcell RH, Young NS. Human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature 1983; 302:426-9.
7. Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149:1153-6.
8. Kurtzman GJ, Ozawa K, Cohen B, Hanson G, Oseas R, Young NS. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 1987;317:287-94.
9. Kurtzman GJ, Cohen B, Meyers P, Amunullah A, Young NS. Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet 1988; 2(8621):1159-62.
10. Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321:519-23.
11. Kerr S, O'Keeffe G, Kilty C, Doyle S. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J Med Virol 1999; 57:179-85.
12. Petrovsky N, Harrison LC. Cytokine-based human whole blood assay for the detection of antigen-reactive T cells. J Immunol Methods 1995; 186:37-46.
13. Viallard JF, Pellegrin JL, Ranchin V, et al. Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1999; 115:189-95.
14. Moller DR, Forman JD, Liu MC, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996; 156:4952-60.
15. Milburn HJ, Poulter LW, Dilmec A, Cochrane GM, Kemeny DM. Corticosteroids restore the balance between locally produced Th1 and Th2 cytokines and immunoglobulin isotypes to normal in sarcoid lung. Clin Exp Immunol 1997; 108:105-13.
16. Minshall EM, Tsicopoulos A, Yasruel Z, et al. Cytokine mRNA gene expression in active and nonactive pulmonary sarcoidosis. Eur Respir J 1997; 10:2034-9.
17. Prior C, Haslam PL. Increased levels of serum interferon-gamma in pulmonary sarcoidosis and relationship with response to corticosteroid therapy. Am Rev Respir Dis 1991; 143:53-60.
18. Broxmeyer H, Lu L, Platzer E, Feit C, Juliano L, Rubin BY. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 1983; 131:1300-5.
19. Zoumbos NC, Gascon P, Trost S, Djeu JY, Young N. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci USA 1985; 82:188-92.
20. Nisticò A, Young NS. Gamma-interferon gene expression in the bone marrow of patients with aplastic anemia. Ann Intern Med 1994; 120:463-9.
21. Balbi B, Moller DR, Kirby M, Holroyd KJ, Crystal RG. Increased numbers of T lymphocytes with γδ-positive antigen receptors in a subgroup of individuals with pulmonary sarcoidosis. J Clin Invest 1990; 85:1353-61.
22. Nakata K, Sugie T, Cohen H, Nakano H, Aoki M. Expansion of circulating gamma delta T cells in active sarcoidosis closely correlates defects in cellular immunity. Clin Immunol Immunopathol 1995 217-22.
23. Hara T, Mizuno Y, Nagata M, et al. Human gamma delta T-cell receptor-positive cell-mediated inhibition of erythropoiesis in vitro in a patient with type I autoimmune polyglandular syndrome and pure red blood cell aplasia. Blood 1990; 75:941-50.